Nephrogenic systemic fibrosis-Implications for nephrologists

European Journal of Radiology

Volumn 66, Issue 2, 2008, Pages 208-212

  Saab, Georges ^a   Abu Alfa, Ali ^b  

^a University of Missouri   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Contrast induced nephropathy; Nephrogenic systemic fibrosis

Indexed keywords

BIOLOGICAL ORGANS; GADOLINIUM; HEALTH RISKS; METABOLISM;

CHRONIC KIDNEY DISEASE; CONTRAST-INDUCED NEPHROPATHY; NEPHROGENIC SYSTEMIC FIBROSIS;

TUMORS;

ACETYLCYSTEINE; BICARBONATE; GADODIAMIDE; GADOLINIUM; IODINATED CONTRAST MEDIUM; RECOMBINANT ERYTHROPOIETIN;

CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; METABOLIC ACIDOSIS; MINERAL METABOLISM; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; RISK FACTORS; SKIN DISEASES;

EID: 43049178336     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.01.028     Document Type: Review

References (32)

1. Grassmann A., Gioberge S., Moeller S., and Brown G. End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 30 12 (2006) 895
2. Wattanakit K., Folsom A.R., Selvin E., Coresh J., Hirsch A.T., and Weatherley B.D. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 18 2 (2007) 629-636
3. Finn W.F. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant 21 6 (2006) i2-i10
4. Bargman J.M., Thorpe K.E., Churchill D.N., and CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 12 10 (2001) 2158-2162
5. Hammer F.D., Goffette P.P., Malaise J., and Mathurin P. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 9 1 (1999) 128-136
6. Spinosa D.J., Kaufmann J.A., and Hartwell G.D. Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography. Radiology 223 2 (2002) 319-325
7. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 4 (2006) 1104-1108
8. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents, St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007;56(7):137-41.
9. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 9 (2006) 2359-2362
10. Broome D.R., Girguis M.S., Baron P.W., Cottrell A.C., Kjellin I., and Kirk G.A. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188 2 (2007) 586-592
11. Marckmann P., Skov L., Rossen K., Heaf J.G., and Thomsen H.S. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3174-3178
12. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 1 (2007) 148-157
13. Othersen J.B., Maize J.C., Woolson R.F., and Budisavljevic M.N. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22 (2007) 3179-3185
14. Yerram P., Saab G., Karuparthi P.R., Hayden M.R., and Khanna R. Nephrogenic systemic fibrosis: a mysterious disease affecting dialysis patients: role of gadiodiamide in causation and the beneficial effects of IV sodium thiosulfate. Clin J Am Soc Nephrol 2 (2007) 258-263
15. Khurana A., Runge V.M., Narayanan M., Greene J.F., and Nickel A.E. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 42 2 (2007) 139-145
16. High W.A., Ayers R.A., Chandler J., Zito G., and Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 1 (2007) 21-26
17. Boyd A.S., Zic J.A., and Abraham J.L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 1 (2007) 27-30
18. Deo A., Fogel M., and Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2 (2007) 264-267
19. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
20. Joffe P., Thomsen H.S., and Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 7 (1998) 491-502
21. Swaminathan S., Ahmed I., McCarthy J.T., Albright R.C., Pittelkow M.R., Caplice N.M., et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145 3 (2006) 234-235
22. Haroon Z.A., Amin K., Jiang X., and Arcasoy M.O. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163 3 (2003) 993-1000
23. Zhang Y., Thamer M., Stefanik K., Kaufman J., and Cotter D.J. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 5 (2004) 866-876
24. Young E.W., Albert J.M., Satayathum S., et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 3 (2005) 1179-1187
25. Termorshuizen F., Dekker F.W., van Manen J.G., Korevaar J.C., Boeschoten E.W., Krediet R.T., and NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15 4 (2004) 1061-1070
26. Dittrich E., Puttinger H., Schillinger M., et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients-a prospective study. Nephrol Dial Transplant 21 5 (2006) 1334-1339
27. Tombach B., Bremer C., Reimer P., et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol 178 1 (2002) 105-109
28. Broome D.R., Cottrell A.C., and Kanal E. Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?". AJR Am J Roentgenol 189 4 (2007) W234-W235
29. Kuo P.H., Kanal E., Abu-Alfa A.K., and Cowper S.E. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242 3 (2007) 647-649
30. United States Food and Drug Administration Public Health Advisory Regarding Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging 23 May 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm.
31. Reilly R.F. Risk of nephrogenic systemic fibrosis with gatoderidol (Prohance). J Am Soc Nephrol 18 (2007) 716A
32. Launay-Vacher, Karie S., Janus N., et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. J Am Soc Nephrol 18 (2007) 775A